Completed PHASE1 INTERVENTIONAL 11-arm NCT01521832

Escalating Dose Study in Healthy Volunteers With SEN0014196

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196

Sponsor: Siena Biotech S.p.A.

Conditions Huntington's Disease

Interventions SEN0014196

Updated 5 times since 2017 Last updated: Feb 6, 2012 Started: Oct 31, 2009 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Huntington's Disease, this trial is completed. The trial is conducted by Siena Biotech S.p.A. and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Siena Biotech S.p.A.

Data source: Siena Biotech S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom